![]() |
![]() |
Legal status
Patent in force
(51) | INT.CL. | A61K 39/395 | (2006.01) |
C07K 16/24 | (2006.01) | ||
A61P 1/04 | (2006.01) |
(11) | Number of the document | 3773715 |
(13) | Kind of document | T |
(96) | European patent application number | 19722256.5 |
Date of filing the European patent application | 2019-03-28 | |
(97) | Date of publication of the European application | 2021-02-17 |
(45) | Date of publication and mention of the grant of the patent | 2024-05-08 |
(46) | Date of publication of the claims translation | 2024-06-25 |
(86) | Number | PCT/US2019/024633 |
Date | 2019-03-28 |
(87) | Number | WO 2019/191464 |
Date | 2019-10-03 |
(30) | Number | Date | Country code |
201862650314 P | 2018-03-30 | US |
(72) |
CANAVAN, James Benedict , US
FRIEDRICH, Stuart William , US
KRUEGER, Kathryn Ann , US
MILCH, Catherine , US
TUTTLE, Jay Lawrence , US
|
(73) |
Eli Lilly and Company ,
Lilly Corporate Center, Indianapolis, IN 46285,
US
|
(74) |
Liudmila GERASIMOVIČ,
IĮ "Liudmila Gerasimovič, Patentinis patikėtinis", Vingrių g. 13-42, LT-01141 Vilnius,
LT
|
(54) | Mirikizumabas, skirtas naudoti gydant opinį kolitą |
MIRIKIZUMAB IN THE TREATMENT OF ULCERATIVE COLITIS |
Payment date | Validity (years) | Amount | |
2025-02-18 | 7 | 162.00 EUR |
2026-03-28 |